Abstract
The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicentered, observational study that was designed to enroll 30,000 hypertensive Japanese patients from more than 3,000 private practitioners. It is the first large-scale observational study to assess the efficacy and safety of losartan, an angiotensin II receptor antagonist, in Japan. Patients were enrolled between June 2000 and May 2002, and followed up to June 2005. The data from 29,850 patients were used for the analysis of safety and efficacy. These patients were treated with losartan mostly at a daily dose of 25–50 mg. The mean follow-up period was 2.9 years. The patients were aged 62.4±12.1 years (mean±SD) and their mean systolic/diastolic blood pressure was 165.3±17.2/94.3±11.7 mmHg (mean±SD). Mean blood pressure in patients who were evaluated for efficacy decreased from 165.8/94.8 mmHg (n=26,512) at baseline to 145.5/84.4 mmHg after 3 months (n=21,269) and 138.6/80.0 mmHg after 36 months of treatment (n=13,879). Blood pressure was well controlled during the study period by losartan alone or losartan-based combination therapy. In nearly half of the patients, blood pressure was reduced to less than 140/90 mmHg during the study period. In addition to its antihypertensive effect, losartan reduced the uric acid level in patients whose baseline uric acid level was ≥7 mg/dL. Losartan also prevented acceleration of proteinuria. Adverse drug reactions occurred in 1,081 of the 29,850 patients. Long-term losartan therapy was effective and well tolerated in Japanese clinical practice.
Similar content being viewed by others
Article PDF
References
Saruta T : Hypertension in medicine and medical care in Japan. Nippon Naika Gakkai Zasshi 2001; 90: 48–52.
World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Chobanian AV, Bakris GL, Black HR, et al: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
European Society of Hypertension–European Society of Cardiology Guidelines Committee : 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension: Guidelines Committee. J Hypertens 2003; 21: 1011–1053.
Japanese Society of Hypertension : Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Wolf-Maier K, Cooper RS, Kramer H, et al: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–17.
Fagard RH, Van Den Enden M, Leeman M, et al: Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297–1302.
Sharma AM, Wittchen HU, Kirch W, et al, HYDRA Study Group: High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004; 22: 479–486.
Ohkubo T, Obara T, Funahashi J, et al, the J-HOME Study Group: Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res 2004; 27: 755–763.
Saruta T : Current status of calcium antagonists in Japan. Am J Cardiol 1998; 82: 32R–34R.
Mori H, Ukai H, Yamamoto H, et al: Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143–151.
Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Brenner BM, Cooper ME, Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z : Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol 2006; 10: 193–200.
Lindholm LH, Ibbsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.
Dickstein K, Kjekshus J : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752–760.
Pitt B, Poole-Wilson PA, Segal R, et al: Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587.
Ueshima H : Changes in dietary habit, cardiovascular risk factors and mortality in Japan. Acta Cardiol 1990; 45: 311–327.
Khor GL : Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 2001; 10: 76–80.
Naritomi H, Fujita S, Ito S, et al: Design and baseline characteristics of an observational study in Japanese patients with hypertension: Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH). Hypertens Res 2007; 30: 807–814.
Culleton BF, Larson MG, Parfrey PS, et al: Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med 2000; 109: 1–8.
Tanihara S, Hayakawa T, Oki I, et al, NIPPON DATA Research Group: Proteinuria is a prognostic marker for cardiovascular mortality: NIPPON DATA 80, 1980–1999. J Epidemiol 2005; 15: 146–153.
De Leeuw PW, Thijs L, Birkenhager WH, et al, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators : Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213–2222.
Wachtell K, Ibsen H, Olsen MH, et al: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901–906.
Mann JF, Yi OL, Gerstein HC : Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl 2004; 92: S59–S62.
Iino Y, Hayashi M, Kawamura T, et al, Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators : Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21–30.
Bakris GL, Weir MR : Angiotensin-converting enzyme inhibitor–associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685–693.
Mangrum AJ, Bakris GL : Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol 2004; 24: 168–175.
Alderman MH, Cohen H, Madhaven S, Kivlighn S : Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144–150.
Franse LV, Pahor M, Di Bari M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–1154.
Nagahama K, Iseki K, Inoue T, et al: Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 227–233.
Nakashima M, Uematsu T, Kosuge K, Kanamaru M : Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333–335.
Tsunoda K, Abe K, Hagino T, et al: Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28–32.
Enomoto A, Kimura H, Chairoungdua A, et al: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447–452.
Edwards RM, Trizna W, Stack EJ, Weinstock J : Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 1996; 276: 125–129.
Hoieggen A, Alderman MH, Kjeldsen SE, et al: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–1049.
Hou FF, Zhang X, Zhang GH, et al: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131–140.
Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS : Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104: 1985–1991.
Raebel MA, McClure DL, Simon SR, et al: Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 2007; 16: 55–64.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Naritomi, H., Fujita, T., Ito, S. et al. Efficacy and Safety of Long-Term Losartan Therapy Demonstrated by a Prospective Observational Study in Japanese Patients with Hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) Study. Hypertens Res 31, 295–304 (2008). https://doi.org/10.1291/hypres.31.295
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.295
Keywords
This article is cited by
-
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Hypertension Research (2019)
-
Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker
Heart and Vessels (2016)
-
Chapter 7. Hypertension complicated by other diseases
Hypertension Research (2014)
-
Chapter 5. Treatment with antihypertensive drugs
Hypertension Research (2014)
-
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial
Hypertension Research (2012)